402 related articles for article (PubMed ID: 32850312)
1. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
3. Expression of Androgen Receptor and Cancer Stem Cell Markers (CD44
Riaz N; Idress R; Habib S; Azam I; Lalani EM
Transl Oncol; 2018 Aug; 11(4):920-929. PubMed ID: 29843115
[TBL] [Abstract][Full Text] [Related]
4. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
[TBL] [Abstract][Full Text] [Related]
6. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
7. Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.
Asleh K; Won JR; Gao D; Voduc KD; Nielsen TO
Breast Cancer Res Treat; 2018 Feb; 168(1):107-115. PubMed ID: 29159761
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
9. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer.
Zou W; Yang Y; Zheng R; Wang Z; Zeng H; Chen Z; Yang F; Wang J
Int J Clin Exp Pathol; 2020; 13(5):1008-1016. PubMed ID: 32509072
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
12. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
16. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact.
Voutilainen S; Heikkilä P; Sampo M; Nevanlinna H; Blomqvist C; Mattson J
Acta Oncol; 2021 Sep; 60(9):1233-1239. PubMed ID: 34282709
[TBL] [Abstract][Full Text] [Related]
17. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis.
Zhang X; Xing C; Guan W; Chen L; Guo K; Yu A; Xie K
Cancer Cell Int; 2020; 20():169. PubMed ID: 32467665
[TBL] [Abstract][Full Text] [Related]
19. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
